Gilead Sciences (GILD) Tops Q1 EPS by 31c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. NVDA
5. STZ
6. MSFT
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to Gilead Sciences (GILD) Tops Q1 EPS by 31c

Gilead Sciences Announces First Quarter 2022 Financial Results

April 28, 2022 4:02 PM EDT

Biktarvy Sales Increased 18% Year-Over-Year to $2.2 billion

Oncology Sales Increased 60% Year-Over-Year to $420 million

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2022.

Gileads performance in the first quarter reflects the strength and diversity of our business with both our HIV and oncology therapies contributing to year-over-year growth, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Biktarvy delivered strong 18% year-over-year revenue growth, and oncology sales increased by 60% year-over-year,... More